Video: Biological Evaluation Under ISO 10993-1:2025 | Duration: 5100s | Summary: Biological Evaluation Under ISO 10993-1:2025 | Chapters: Welcome and Introduction (24.145s), Key ISO Changes (232.74s), Key ISO Changes (802.945s), Biological Evaluation Update (1297.22s), Q&A Session (1726.835s), FDA Standard Recognition (1877.39s), Documentation and References (2022.6s), FDA Standard Recognition (2108.89s), Complex Risk Management (2200.725s), Ethylene Oxide Safety (2328.63s), Colorant Safety Evaluation (2417s), Long-Term Biocompatibility Assessment (2602.12s), Aging in Implants (2708.995s), Concluding Q&A Session (2826.92s)
Transcript for "Biological Evaluation Under ISO 10993-1:2025":
Okay. Hello, and welcome to our today's keynote about biological evaluation according to ISO 10,090 three-one. We will talk today about the revision which was published in November, the one from 2025, and I will present to you today the most relevant changes to you about this new, very interesting standard. First, I want to introduce myself. My name is Sylvia Georges. By education, I'm a biologist. I did my PhD in neuroscience in the wonderful city of Tubingen. It's a little town in Baden Wurttemberg, Germany, in the really South Of Germany. And since 2018, I'm with NSF. First, focused on clinical evaluations and clinical studies with a general focus on biostatistics there, before we started in 2019 to develop the service around biological safety of medical devices here at NSF. We focus on ISO 10,193, but also on ISO 18,562, and we have a team. I'm manager medical consulting along with my colleague. We are managing a team in clinical affairs and biological safety. It's around 20 well experienced people, well educated people, mostly natural scientists, and most of them with a PhD really, yeah, living for doing science, and they really like the topic of biological safety. NSF itself is a global nonprofit organization with a mission to protect and improve human and planet health, and we follow this mission in three core industries. There's food and nutrition, there's water, and there's life sciences. And our division of Medical Devices and also IBD and pharma is located in the division of life sciences. We have four solution areas. In general, it's pharma and biotech, combination products, medical devices, and IVDs. And our services focus on auditing, consulting, including documentation. So we yeah, we conduct every documentation for the entire technical documentation for you, but we also provide training and workshop, in house training tailored to your medical device, to your company, to your team, whatever you need. At NSF here in Hamburg, I'm personally located in Hamburg, and the medical device division for EMEA is located in Hamburg. We are here since 1999, and our services are all our services, from the first idea of a medical device until disposal of the medical device and everything is in between, is certified according to ISO thirteen thousand four and eighty five. So we have a quality management system in place according to the standard and have a certificate, which brings the advantage of relaying supplier audits, for example. So we heard from our clients that they just showed the notified body the certificate, and they do not have to do supplier audits. That's really an advantage. Yeah. This is NSF, NSF Hamburg Medical Devices, devices, and me in a nutshell, which brings us to our today's agenda. I will focus on three points. As promised, the key changes of the new ISO 10,090 three-one from 2025, which you see here on the right side. Then I go over to how to document a biological evaluation. Spoiler, it's still a three tiered approach in biological evaluation plan, biological evaluation report, and the risk management file, mostly the risk analysis table. And the final point today is the big question, do I need to reevaluate my existing biological evaluation in response to this new standard? Yeah, here on the right side is the cover page of this new standard, and the first thing which comes to our eye is the title was changed. Before, it was evaluating and testing within the risk management process, and now its requirements and general principles for the evaluation of biological safety within the risk management process. So the focus is still on the risk management process, which is also really important and really helpful. Yeah. So let's dig in. The key changes of ISO 10,193 dash one, and the first key point is the greater alignment with the risk management framework according to ISO fourteen thousand nine seventy one. It was there before, the requirement was there to conduct a biological evaluation according to a risk management process with ISO 14,971, but it was really complicated, and it was difficult to interpret which steps in the biological evaluation mirror which process steps in the risk management process according to 14,971. And now this was really clarified. On the left side is the flowchart, which is depicted in the ISO 14,971 and the committee which wrote the revision of ISO 10,000 and three-one copied it directly from the ISO fourteen thousand nine seventy one. Okay, there should be animations. Doesn't matter. We have color coding to help us. The beauty in this new standard is that the entire standard was restructured and aligned according to this risk management process on the left hand side, and it's all shortly demonstrated in this Figure two, in this flowchart, which depicts the biological evaluation process. And on the left side, in green, I marked for you the yeah, the pandans, the representations of the risk management process on the left side, which is the language in fourteen thousand nine seventy one and on the right side, the language in ISO 10,993. At the top, you'll see the big challenge of risk analysis with the description and categorization according to contact type, contact duration, the identification of characteristics relevant to biological safety, so it all focuses on biological safety. Of course, including chemical, physical, biological information. Then there comes the identification of hazards, not only product specific hazards, but also biological hazards as recommended to evaluate by the standard. And finally, the definition of acceptability criteria in order to be able to do the risk evaluation, which comes then in the second step below, followed by the risk control, followed by the risk management review, which we usually document in the risk management report. And finally, the product can go into the market, and there come this post market surveillance activities. So it's clearly mirrored now, and it's really helpful. We know exactly what to do, and it brings us advantages. For example, the risk based approach. I have some examples here, three of them. On the left side, at the top, there is a blood pressure monitor. It's a device which has a very low risk profile. It's in contact with intact skin. There's a skin barrier between the materials and substances, and let's say the biological system. And in my example, it's only one examination, and the contact duration is shorter than twenty four hours. Maybe the plastics is commonly used plastics, which you also have in your keyboards and your mouse in front of you. The materials is used since decades for this intended purpose and for this specific device, so there's no unknown risk in this medical device to assume. And so, in this example, available data might be sufficient safety data sheets for the plastics or toxicological data from databases. There's certainly no need to conduct chemical characterization or even animal testing, something like this. In the center as an implant, it's the opposite. It's really highly invasive contact type and a very long contact duration, hopefully thirty years instead of thirty days, and for this, you really need a detailed biological evaluation, whereas if there are data gaps for the blood pressure monitor, you may still be able to conduct risk assessment. For the implant, it may not be the case, and you need all of the data which you can get, right? Available data, chemical characterization, as well as biological safety data, and maybe even animal testing. The bottom example is also an implant. It's also very invasive, long duration. The difference here is that often the materials are standardized, for example, to ISO 5,832, and we made the experience several times with different reviewers from the notified body that they say, We rely on standardized materials. We know they are safe. If they are standardized for this intended purpose, just focus on the residues from manufacturing, from cleaning, from sterilization, conduct the chemical characterization, do your toxicological risk assessment according to 10,100 three-seventeen, and that's it. So we can just leave the constituent materials aside, which is also a big advantage in the risk based approach. Yeah, another process or another consideration in the risk management process is the reasonably foreseeable mis use. It was included now in the new standard. There was no focus before. The reasonably foreseeable misuse is defined as the use of a product or a system in a way not intended by the manufacturer, meaning it's not described like that in the IFU, but which can result from readily predictable human behavior. So you do not need to do detailed exercises and getting abstract ideas about what could happen with your device. It just should just be readily predictable. Maybe it's even reported in a literature or something like that. I brought some examples here. In the back, you see a plaster. It's just a wound dressing, and let's imagine this wound dressing is intended to cover the wound for up to twenty four hours for a limited contact duration. I know this is a little bit an abstracted example, but it's an example, right? And afterwards, you should remove this wound dressing or this plaster, and let your wound heal on dry air. You can readily predict that a patient may use or may wear this plaster for longer than twenty four hours. This would be such an example for reasonable foreseeable misuse. The second example further to the front is remanufacturing processes, which are maybe not conducted according to validated processes, like it is described in the IFU, but maybe something is changed, other cleaning agents are used, or something like this, which may have an impact on the residues to which the patient is indirectly exposed to, and which might have an impact then on the biological safety of the patient. This is also reasonably foreseeable misuse. A further example is a medical device, which is here the cream at the front, used on different application sites as intended, or different tissue types as intended. So imagine you have a cream or something which you use only on intact skin, but you could imagine that a patient may use it if he or she has a cold at the nose and the skin is somehow compromised, that the screen is also used under the nose, or something like this. Or also other patient populations. You may have a medical device designed and manufactured for adults only. It's described like that in the intended purpose, but there may be no alternative for children. So it's readily predictable that a pediatrician may describe this medical device for children's use also, so this would also be another example. So this is not an abstract example, so don't exaggerate. Just think about what could happen in this sense, and this should be considered in your biological evaluation. Yeah, this was the first most relevant change, and also the biggest one, and the reason for all this restructuring of the text in the standard. The second most relevant change is the extended contact duration in specific cases for specific medical devices. The committee introduced a contact day, which means if patient is exposed to the medical device and its materials and substances which come with the medical device, it doesn't matter how long this contact is, it's always considered one entire contact day. So you always have at least limited contact duration, but for specific cases and devices which are used repeatedly on the same patient, you immediately go into prolonged or even long term use, because each contact is counted as one entire contact day. So there's no cumulative use anymore, and you may stay within one day. It's always longer than a day if you have repeated use. The other example, the other introduction, is the term of bioaccumulation. As soon as you have an indicator that a substance or a material bioaccumulates in the system, in the tissue, wherever, then you categorize your device as long term contacting medical device. Yeah, this is a relevant change. The third one is our beloved comprehensive table A1. It doesn't exist anymore. I don't know. Say goodbye to the table, but it was divided into smaller category specific tables and integrated in the main text. It belongs now to exactly to the chapter where these individual tables belong to. So they talk about contact with intact skin, and there is the table, and that's really intuitive and really nicely done, in my opinion. There are four tables. The first one is for medical devices in contact with intact skin. The second one is for contact with intact mucosal membranes. And the third one is a really big one, comprising all medical devices in contact with, I say, exposed skin. So as soon as you have breached or compromised skin, be it skin or mucosal membrane or internal tissues other than circulating blood, then you go and categorize your medical device according to this table three, which remains table four, medical devices devices in in contact with circulating blood. And you find your formerly known endpoints in this table in the specific chapters, which give you guidance on the categorization of these contact types. The fourth most relevant change belongs to the endpoints. They are no longer called endpoints, they are now named biological effects. And there were some changes in the biological effects themselves. First, the systemic toxicity is now introduced as a general category. You know there were acute systemic toxicity, subacute, subchronic, and chronic. And the subtypes of systemic toxicity, so to say, to evaluate, is now dependent on the duration of use. So the longer your contact duration, the longer should the evaluation period of your systemic toxicity are. So keep in mind that this should be aligned, but it's not that present anymore in the tables. The implantation effects have been renamed, which I find was a really important step to do. It's now called local effects after tissue contact. I found it always very, I don't know, not very intuitive to say I have a device which is in contact with intact mucosal membrane, and as soon as I have prolonged or long term contact, I should evaluate implantation effects, but there's nothing implanted. Or we had an example where there was a wound wash, and it rinsed through the wound and cleaned, and they rinse afterwards with saline. Nothing is implanted there, but we were supposed to evaluate implantation effects. That was not very intuitive, so I really welcome this idea of renaming the implantation effects. Material mediated pyrogenicity was removed from the table and also from the focus of the entire standard, because there is not much material from which you may make medical devices which elicit pyrogenic activities. You should evaluate pyrogenicity only in constituents where you know that they have previously elicited a pyrogenic response or if you have no clue. If you do not know, if you have another material and you just do not know what the biological effects are, then you check for pyrogenicity. Otherwise, yeah, consider state of the art and check if, yeah, if it's a commonly used medical device material, and usually, it doesn't elicit a pyrogenic response. The evaluation of genotoxicity is now broadly required. In general, it's required as soon as you have a device in prolonged contact, as long as the contact is not with intact skin. Then genotoxicity should be evaluated, and the related carcinogenicity is evaluated if you got an indicator that a genotoxic constituent is present, or there are non genotoxic mechanisms, biological mechanisms. They should be evaluated as soon as you have a device in long term contact, because these mechanisms just take time to get into action, and prolonged or limited contact duration is just too short to, yeah, to be activated. So, and the final changes aren't actually changes. So the changes which I discussed now are really changes, relevant changes. On my slide here, I just show certain topics which got more emphasis, but they were there before. The evaluation should be conducted over the entire life cycle of the medical device, which is aligned with the risk management, right? As soon as you find your first material and you get into evaluation of this material, it's suitable for this intended purpose biologically, chemically, physically, you do an evaluation, which should be documented in your risk management profile or risk management file. So far, you can immediately, or you should immediately do it in the biological evaluation. And then follow design, manufacturing, clinical application, all the way, and all the processes which the medical device undergoes until disposal. This should be considered in your biological evaluation. Clinical data can be included. It could be included before it was named history of safe clinical use. You can use clinical data if it's relevant to the specific biological effect, so the relevance should be evaluated quality and type of clinical information. For novel materials, you got the idea before, the evaluation is more detailed and more rigorous. It has more endpoints, because novel materials are usually not commonly known, and the risk profile needs to be evaluated before we yeah, before we know something about these materials. And the sensitive population usually we focus in the intended purpose on adults or children, maybe children with different ages, neonates, something like this, adolescents. But consider also sensitive population, like chronically ill person, or elderly persons, immunocompromised persons. If this is a patient population for your device, this should be considered in the biological evaluation. Yeah. Those were the most relevant changes. It's really a lot for this revision of the ISO ten ninety three-one, but I think it was a big improvement, and it's really more intuitive to work with this standard, which brings us to the documentation biological evaluation. I said before, it's still a three tiered approach. It all starts with the biological evaluation plan, which is part of the risk management plan. Here at the top, I exploit this Figure two again, and we see the risk analysis and all the information, which you gather and collect to conduct the risk analysis, to define the acceptability criteria, to do your risk estimation, the values for the probability of harm, and severity of that harm. All this data should be documented in the biological evaluation plan, in addition to description, and hazards, and all the stuff, of course. In addition, you document the strategy and plan content for the report. The criteria to evaluate the overall biological safety conclusions for the finished medical device, not individually for materials or components of something, it all goes to the finished device and make a statement about the biological safety of the device. Aspects requiring specific technical competencies and responsible personnel should be documented, which is really important here. We get frequently feedback from notified bodies saying, it cannot be done all by the risk manager, for example, or one person. There are certain qualifications which need to be covered, be it science, data research, literature research, material science, it comes from R and D. Is a material suitable for its intended purpose? Regulatory affairs, right? Knowing the requirements of 10,993, 14,971, something like this toxicology data, how do I interpret biological safety test reports, something like this. And they assume or they what they repeatedly state, it cannot be all in one person. It should be a team comprising all these qualifications, which or who work on this biological evaluation. Which brings us to the report. There are a lot of statements and a lot of, yeah, outcomes of management. So the acceptance criteria should be stated again in line with the BEP. This is the box at the top right here. Conformity with the BEP, or if there were discrepancies, then describe them. How each biological effect has been addressed, available data, testing, chemical analysis, something like this. Interpretation and assessment of data, including relevance to the finished device. Here, there is it again. A rationale for the selection, but also for weighting of testing. Whatever you do, if you do so for each individual biological effect, you should have a statement if you tested yes or no, and why. Use of non standard test methods. This is usually the case for in vitro alternatives to animal testing. The outcome of biological risk evaluation, risk control measures, and the identified residual biological risk. This is just the outcome of the risk management file after you finished your risk management process. Right? And again, the report should be prepared by verifiably competent personnel, and the expertise should be documented or demonstrated by the CV. Everything else in the center, which is not blue or yellow, is documented either in the risk analysis table mostly, or the remaining part of the risk management file, or the post market surveillance documentation, which accounts for the bottom of this flow chart. Yeah, which brings us to the final and most relevant question, or very important question: Do I need to update my existing biological evaluation in response to the publication of this new standard? And to tackle this question, I made a flowchart. It's yeah, it's aligned with clause six sixty two in ISO 10,090 three-one twenty twenty five. We start at the top. If you have a biological evaluation in place, it's with the technical documentation, and it's all, yeah, in the shelf, you demonstrated and established an acceptable safety profile, so no retesting is needed. You just need testing if you need information to conduct risk assessment, but if the biological evaluation is done, and it's already archived, then you do not need any information, right? The first step which you do is you review historical information for any changes with impact on biological safety profile. So was there a change in the supplier, a change in material, a change in the manufacturing process, or something like this? If yes, you need to reevaluate and update your biological safety evaluation, but you should have done that already with the 2018 version, so this is completely independent from the new revision. If there is no change, then review if, according to the new standard, additional biological effects are applicable. And they are applicable, as I told you before, if the contact duration is longer than before, then usually more biological effects need to be evaluated, or if you have bioaccumulation. If additional biological effects are applicable, then you need to update your biological evaluation according to the new standard. If not, you can just leave it. It's all fine. The safety profile is as it was, and you just document a justification that you reviewed the process, and there is no reason to update it in accordance with clause six sixty two, and yeah, document it in the technical documentation. This brings me to the end of our keynote today. I summarized on this slide our services in relation to biological evaluation. It's basically everything. Whatever comes to your mind, whatever question you have, contact us and we will help you. We have further webinars like this one, but also longer sessions, online seminars, whatever, to different topics, IVD, medical devices, pharma. Yeah, You own sessions with this QR code. The next one is really nice. It brings you the regulatory update of q one. We do this four times a year. And, we tell you what MDCG guidance on you, or what are discussions in the committees, or something like this. So you learn the first what happens in the regulatory field of medical devices. Then you can contact us via different sources. We have the website, we have social media and email, or just call us. You can just call us with this number, and if it's related to biological evaluations, or also clinical evaluations, you can just call me directly. Here's my contact information, phone number, email, and I'm happy to talk to you. So now we have some time left. If you have any questions, just type them into the chat. Unfortunately, we do not have the opportunity to talk to each other, but this doesn't matter. I hope you brought all your questions related to the new standard. Type them into the chat. I will pick them up and discuss them with you. And if time is not enough, then I will come back to you via email. Thank you so much for your attention so far. There is no question there. Okay, there we go. Please explain differences of contact duration for a device in use two hours per day for Okay, read more for ten days. Please explain differences of contact duration Well, it would be ten days. Right? According to this introduction of the new term contact day, it doesn't matter if it's two hours. If it's two hour per day, it counts as one entire day. And if it's repeatedly used every day, two hours on each day, it's ten days. So you extrapolate your contact time. Is it five minutes or is it two hours? Is it twenty four hours? Doesn't matter. It's always calculated as one entire day. Do you have a template for a gap analysis for the legacy devices? I assume you refer to the gap analysis between the old standard and the new standard and whether your biological evaluation covers the requirements of the new standards. That's what I assume. At the moment, we do not have a template in place, but we are working on one template, which will be done well next week, the week after next week. So it's not long, and we will have this template to, yeah, to conduct this gap analysis. Okay. Is this music coming from the webinar? I do not hear any music. When is FDA expected to recognize this standard? Is there an update? This is really an interesting question. Thank you very much. So every day, I go to the recognized consented standards webpage of the FDA, and I search for 1090Nine-three-one. There is still the revision of 2018 in there, and we do not expect a guidance document like we had before in the near future, but we had some discussions with our clients. They are, well, often in connection with the FDA. And the reviewer of the FDA was repeatedly pointing to pyrogenicity tests and MMP tests, material mediated pyrogenicity, and it was a big discussion whether to do this testing or not. And the new standard was released, and suddenly this discussion went down the priority list. So the reviewer said, Well, this is not important anymore. Let's focus on something different. So this gives us a hint of acknowledgment of the new standard. So they, well, apparently it's not bad, but there is no further information on this one. Let's see. If the medical device contacts breached oral mucosa, this update now would classify the contact as breached and compromised surface instead of mucosal membrane? Well, exactly. This is in Table three. Table three comprises all the tissues which are somehow compromised, breached, hurt, somehow exposed. There is no skin barrier. There is no barrier of the mucosal membrane anymore. The tissue is exposed to the environment, and in these cases, you use Table three. Because, yeah, it's you can also do it by exclusion, right? The first one is intact skin, the second one is intact mucosa, the fourth one is circulating blood, and it doesn't belong to these contact category yeah, contact category types. So it's table three for exposed tissue. Is it expected to duplicate information in biological report and risk report? No, no. You can work with references. That's also feedback from notified body, which we usually get. They do not want to read it twice. It's all one risk management process. So usually, there is one reviewer. And if you refer from the plan to the risk management file and to the report and back, so all three documentation should refer to each other, it's totally fine. You can document each step once. We recommend to document, however, the estimation, the risk estimation, where you assign values of the probability of occurrence of harm and the severity of that harm in the biological evaluation plan, along with the data where you get these values from, because the table, the risk analysis table, usually only states the values, and you need to show where do these values come from. So here, it makes sense to document it twice in the risk analysis table, and also in the plan. Same for the acceptability criteria. Ah, there was a question if we shared a recording or slides. The answer was given right away. We shared the slides. Yeah, I missed that before. Thank you. So for the PharmaLed combination product, prefilled syringe co packed products with the drug, do we need to do this GAP analysis for the new change? Well, you have a medical device component, you have a pharma component, and for the medical device component, this is just according to clause six sixty two, this is the process. So review this change if there was a change, a biologically relevant change. If there was no change, then review if you have additional biological effects. That's the process to follow. And if not, then document that you reviewed and a justification that you do not update and the reason for this decision. Thank you for this question. Yeah, this is also an important one. Then we have here again, when is the FDA expected to recognize the standard? I referred to that already. Yeah, this is really important, right? But the FDA is not that fast. The last revision from 2018, the guidance document for biological safety evaluations from the FDA was updated in 2023, so they take some time. I would rather check the page of recognized consensus standards, and this might be earlier. Okay, what do we have? Oh, wow. This is a long one. Thank you very much. However, in my opinion, this approach is going to make development of the large, complex devices with significant biological risk even more complicated. In my opinion, this approach is not within the ISO fourteen thousand nine seventy one frame, but rather the duplication of the framework. But most of risk evaluation can take place really late in the development, already at the right side of the V model, which does not assist the manufacturers to develop biocompatible products, and the risk of failed testing is huge. Oh, yeah, there may be well, yeah, there may be really complex medical devices, which makes this entire risk management process as complex as it is. But in the end, the biological evaluation documents in the plan the data which is used to conduct the risk management, right? So it may be complicated because of the recommended biological hazards, which were formerly endpoints, but I think the remaining part is exactly what you do in your risk management file, right? You follow the risk analysis, you identify your device specific hazards, you add up the biological effects, then you check on your available data, do a GAP analysis if the available data is sufficient for your risk estimation. If it's not sufficient, you generate the data. And that's the yeah, I think that's the challenging part, right, to find independent on the complexity and risk profile of the medical device, to find the reason to do testing or not testing. So when is the data gap significant, and when isn't it significant? And this depends on the ability to conduct the risk estimation, and finally, the risk evaluation. But yeah, it's certainly for systems of medical devices, it's certainly complicated, yeah. I agree. Do you have typical examples of reasonably foreseeable misuse? This may be a showstopper for some devices. Example for ethylene oxide residual testing if you change body mass from ten kilo children to five kilogram, very low birth weight neonates. Yeah, well, I presented some typical examples. From the top of my head, I have them, which I presented to you. Yeah, but this is true. So for patient populations, there is this threshold testing, and you have ethylene oxide residues, which are really toxic. Therefore, we have an entire standard, the ISO 10,090 three-seven, -seven, to make the basically, it's a toxicological risk assessment on ethylene oxide and its metabolites. And the threshold, yeah, it's maybe too high for neonates and Okay for ten kilogram children. But if you conduct ethylene oxide testing, and you want to treat low birth weight neonates with your medical device, you should be sure that this device is is safe. Right? Yeah. We can check on the ISO standards again and maybe discuss this topic on the phone. This is really interesting. Then what do we have here? If the colorant in a medical device is changed, is there a possibility to avoid conduction of studies? What kind of documentation would be needed for the colorant? So what we we usually follow a process. It's this stepwise approach given by, first, the ISO 10 three-one, but also other standards, like ISO ten ninety three-eighteen -twenty three-ten, they all propose this stepwise approach to first exploit available data. And there, we check for safety data sheets. And in chapter 11, they are all regulated according to the REACH regulation in Europe. Well, REACH use REACH also in The US. Now I lost it. Colorants. Yeah, first, we check safety data sheets, and Chapter 11 is the toxicological data. If there is toxicological data, it's often missing, I admit. Then we go with if we have CAS registry numbers or something like this, or a name, a general chemical name, we go into toxicological databases like ECAChem or PubChem or something like this, and we search for toxicological data there, in line with our predefined hazards, right? Mostly the endpoints or the biological effects, as recommended by the standard. We type in the CAS registry number, and if we do not have this number, we get maybe the chemical structure or chemical family name. This data, which results then from this research, is not that specific for my substance, but it may give you an idea if the substance or this colorant is toxic, yes or no. Afterwards, we conduct if you're still missing information, we do always do after each step, do a gap analysis. Afterwards, we go into the literature search, But the more available data sources we exploit, the less relevant gets the data in, so specifically for our substance, which we want to evaluate. And finally, if available data is exploited and there's nothing to do, you can do a chemical analysis or chemical characterization, followed by a toxicological risk assessment, if you get the idea from the results that there may be a substance of concern, or an irritating substance, or something like this. And afterwards, if you still need information, you still do not have an idea, and you still are not able to conduct your risk assessment, you go into biological safety testing. That's the process which we follow for every substance and every material. First, conduct the material characterization and check what we have, and afterwards follow this research line from available data up to biological safety testing. What would be a reasonable strategy to assess biocompatibility for devices with very long life, e. G. Typical mechanical ventilator has a lifespan of fifty years? Oh, yeah, we had that once. It's long term contact, right? The strategy of ISO 10,190 three-one in the evaluation from the evaluator perspective, but also from the committee perspective, who write these standards and update these standards, is worst case. You always consider worst case. And if worst case doesn't work, for example, a toxicological threshold is too low and a substance is considered toxic or harmful to children, but not in adults, or something like this, you go into risk control and consider your clinical evaluation level. So you come away from this worst case assumption and go more into the direction of clinical application. This is already a risk control measure, in the sense of the biological evaluation, and then you get, yeah, more realistic data and a more realistic toxic profile. But in the end, you have your contact duration strategies, and it's longer than thirty days. And thirty days, so long, this long term category accounts also for thirty years. So see my examples with the implants. The dental implant, orthopedic implants, they are hopefully worn for twenty years or more, and they belong into the category of longer than thirty days, so long term contact duration. Okay. Those are all great questions. This is really nice. It gives me really a picture what what tackles you, what keeps you busy at night. Yeah. Aging must be accounted for. We are talking about plastics. That's a challenge. I admit, we have repeatedly discussion discussions with notified bodies, especially FDA, as the FDA is pointing to aging. And yeah, sometimes accelerated aging is not enough, but still a good representative for aging in these cases. Once we had but it was orthopedic implant, it was with standardized materials according to this 5003 and '83, 5830, whatever, this standard for orthopedic implants. So the focus was not so much on constituent devices, but there we tackled it theoretically. We did a literature research on particles or ions, I think it was ions, released from the metal parts during wear. And we found literature that after five to fifteen years, there are toxic metal parts released from the alloys, which are implanted into the yeah, into the tissue, into the bone, wherever. And it's this extracellular fluid which works on these alloys and, at some point, after a couple of years, releases then these toxic elements from the alloys. Yeah, this would tackle theoretically, and we made an evaluation on this, but aging is always a discussion. Yeah, with the FDA, maybe, so we recommend to talk to them in advance. But it's, yeah, it's sometimes trial and error, right, how to tackle aging. Okay, I take the last question here. Is chemical characterization and toxicological risk assessment sufficient to waive endpoints such as cytotoxicity, irritation, sensitization, and systemic toxicity? Partly, I must say. Yeah, this is an important question. It's repeatedly stated in the standards. There is twenty one seven hundred twenty six, where this TTC values come from, the threshold of toxicological concern, it's stated there very prominently. But also in ISO 10,000 three-seventeen, that you can use a toxicological risk assessment only on systemic endpoints. So there is no possibility to use it for cytotoxicity, irritation, and sensitization, namely local endpoints, so to say, or how they name it. For this, you use the data and conduct risk the risk management system. So you go along the way, risk management system, and conduct biological safety data directly available via literature or toxicological databases, or you go into testing, but you cannot use toxicological risk assessment according to 10,000 three-seventeen for this one. Systemic toxicity, yes, that's possible. Okay, I'm happy about these great questions. I hope I could you could give you a good overview and some of your specific answers to these questions. We will check if there are additional ones. If I miss some, we will come back to you later. I thank you so much for your attention today, and have a great weekend.